Doxa AB, a Swedish biomaterials company have treated their first patient using a revolutionary high strength, bioactive ceramic material. The event took place when surgeons at Akademiska University hospital in Uppsala repaired a distal radius fracture through minimally invasive injection of the Doxa material.
Doxa’s new material treatment results in complete chemical integration between the material and bone within a matter of moments.
"The first clinical use of our material in orthopaedics represents the culmination of years of work, and a significant milestone for Doxa," commented Peter Bramberg, President and Chief Executive Officer. "These clinical trials will validate that the DOXA technology will effectively address the issues of concern with the current generation of biomaterials, and set the standard for the next."
Doxa has developed a platform of materials having superior strength, variable handling characteristics and programmable properties. The company plans to begin clinical trials for vertebral compression fractures in March, and has targeted numerous other orthopaedic and spinal applications.